

Safety of COVID-19 Vaccine in 5-11 Year Olds

In Ontario, almost 1 million doses of pediatric Pfizer-BioNTech Comirnaty COVID-19 vaccine (approximately 600,000 first doses and 355,000 second doses) have been administered to 5-11 year olds.

More than 50 countries, including Canada, have expanded their COVID-19 immunization programs to include 5-11 year olds with a pediatric formulation of the Pfizer-BioNTech Comirnaty COVID-19 vaccine.

Of the almost 1 million doses of pediatric COVID-19 vaccine administered in Ontario:

0.02%

Of all doses were associated with an adverse event following immunization (AEFI).

98.4%

Of AEFIs were non-serious. Half occurred on the same day as vaccination.

Most commonly reported specific adverse events:

45.1%

Allergic skin reaction

13.7%

Rash

8.8%

Syncope (fainting) with injury

0.0003%

Of all doses were associated with an AEFI involving hospitalization.

1

Case of myocarditis / pericarditis has been reported following immunization.

Data current as of February 27, 2022.

COVID-19 vaccine protects Ontario's kids

Immunization lowers the risk of getting and spreading the virus that causes COVID-19 to others

Vaccination can prevent serious complications including hospitalization, acute severe illness, multi-system inflammation syndrome in children (MIS-C) and post-acute COVID-19 conditions (long COVID).

Ongoing monitoring ensures vaccine safety

Ontario continues to closely monitor vaccine safety data in collaboration with local, provincial, territorial and national partners.

Connect

For the most up-to-date AEFI surveillance reports and instructions on how to report an AEFI, visit publichealthontario.ca/COVID19Vaccines.

For more information visit publichealthontario.ca